3.40
전일 마감가:
$3.35
열려 있는:
$3.34
하루 거래량:
244.46K
Relative Volume:
0.14
시가총액:
$160.82M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-4.5333
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
+7.26%
1개월 성능:
+53.15%
6개월 성능:
-28.50%
1년 성능:
+2.10%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALDX
Aldeyra Therapeutics Inc
|
3.40 | 160.82M | 0 | -44.80M | -30.67M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.90 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
520.64 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.58 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
561.89 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.62 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
2024-04-02 | 재개 | H.C. Wainwright | Buy |
2022-04-27 | 재개 | H.C. Wainwright | Buy |
2021-02-08 | 개시 | H.C. Wainwright | Buy |
2020-12-16 | 개시 | Berenberg | Buy |
2020-10-30 | 개시 | Jefferies | Buy |
2020-10-16 | 개시 | BTIG Research | Buy |
2020-09-22 | 개시 | Alliance Global Partners | Buy |
2020-05-12 | 개시 | Oppenheimer | Outperform |
2018-12-04 | 개시 | Citigroup | Buy |
2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
2018-09-13 | 개시 | Janney | Buy |
2018-01-26 | 개시 | Seaport Global Securities | Buy |
2016-09-26 | 개시 | H.C. Wainwright | Buy |
2016-07-01 | 개시 | Stifel | Buy |
2015-07-01 | 개시 | Canaccord Genuity | Buy |
2015-03-25 | 개시 | Chardan Capital Markets | Buy |
2015-03-20 | 재확인 | H.C. Wainwright | Buy |
2014-11-18 | 개시 | H.C. Wainwright | Buy |
2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive
Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com
Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa
Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus
Aldeyra resubmits Reproxalap's marketing application to FDA - Seeking Alpha
Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application f - GuruFocus
Aldeyra (ALDX) Resubmits Drug Application for Dry Eye Treatment to FDA | ALDX Stock News - GuruFocus
Aldeyra Resubmits Reproxalap NDA to FDA - TipRanks
Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan
Aldeyra Therapeutics Holds Annual Meeting with Key Votes - TipRanks
Trend Tracker for (ALDX) - news.stocktradersdaily.com
Two Sigma Investments LP Sells 15,349 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
161,926 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Millennium Management LLC - Defense World
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Mackenzie Financial Corp Purchases 36,160 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
BNP Paribas Financial Markets Trims Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Bank of America Corp DE Reduces Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ProShare Advisors LLC Acquires Shares of 14,031 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Two Sigma Advisers LP Sells 84,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire
Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World
D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance
HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World
Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World
Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World
ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus
(ALDX) Trading Report - news.stocktradersdaily.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
(ALDX) Trading Advice - news.stocktradersdaily.com
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView
Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aldeyra Therapeutics Inc 주식 (ALDX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Machatha Stephen | Chief Development Officer |
Aug 12 '24 |
Sale |
4.74 |
16,041 |
75,975 |
236,771 |
Greenberg Bruce | See Remarks |
Aug 12 '24 |
Sale |
4.74 |
10,834 |
51,313 |
126,382 |
자본화:
|
볼륨(24시간):